Subtotal versus total gastrectomy for remnant gastric cancer: a systematic review and meta-analysis of observational studies

Author(s):  
Ryota Otsuka ◽  
Koichi Hayano ◽  
Masahiro Yoshida ◽  
Hironobu Goto ◽  
Yusuke Muneoka ◽  
...  
2017 ◽  
Vol 20 (17) ◽  
pp. 3183-3192 ◽  
Author(s):  
Yanhong Huang ◽  
Hongru Chen ◽  
Liang Zhou ◽  
Gaoming Li ◽  
Dali Yi ◽  
...  

AbstractObjectiveTo examine and quantify the potential dose–response relationship between green tea intake and the risk of gastric cancer.DesignWe searched PubMed, EMBASE, Web of Science, CBM, CNKI and VIP up to December 2015 without language restrictions.SettingA systematic review and dose–response meta-analysis of observational studies.SubjectsFive cohort studies and eight case–control studies.ResultsCompared with the lowest level of green tea intake, the pooled relative risk (95 % CI) of gastric cancer was 1·05 (0·90, 1·21, I2=20·3 %) for the cohort studies and the pooled OR (95 % CI) was 0·84 (0·74, 0·95, I2=48·3 %) for the case–control studies. The pooled relative risk of gastric cancer was 0·79 (0·63, 0·97, I2=63·8 %) for intake of 6 cups green tea/d, 0·59 (0·42, 0·82, I2=1·0 %) for 25 years of green tea intake and 7·60 (1·67, 34·60, I2=86·5 %) for drinking very hot green tea.ConclusionsDrinking green tea has a certain preventive effect on reducing the risk of gastric cancer, particularly for long-term and high-dose consumption. Drinking too high-temperature green tea may increase the risk of gastric cancer, but it is still unclear whether high-temperature green tea is a risk factor for gastric cancer. Further studies should be performed to obtain more detailed results, including other gastric cancer risk factors such as smoking and alcohol consumption and the dose of the effective components in green tea, to provide more reliable evidence-based medical references for the relationship between green tea and gastric cancer.


PLoS ONE ◽  
2018 ◽  
Vol 13 (8) ◽  
pp. e0203120 ◽  
Author(s):  
Shijiao Yan ◽  
Yong Gan ◽  
Xingyue Song ◽  
Yunqiang Chen ◽  
Na Liao ◽  
...  

2021 ◽  
Vol 8 ◽  
Author(s):  
Peng Miao ◽  
Lin Guan

Background: Many case–control studies have investigated the association between dietary cholesterol and gastric cancer, yielding inconsistent findings. We carried out a systematic review and meta-analysis of observational studies to assess the relationship between dietary cholesterol intake and gastric cancer among adults.Methods: PubMed, Scopus, and Google Scholar were systematically searched to identify articles that evaluated the association of dietary cholesterol with gastric cancer up to May 2021. Pooled odds ratio (ORs) and 95% confidence intervals (CIs) were computed using random-effects models. Dose–response analysis was used to explore the shape and strength of the association.Results: Fourteen case–control studies with 6,490 gastric cancer patients and 17,793 controls met our inclusion criteria. In the meta-analysis of the highest vs. the lowest dietary cholesterol categories, a significantly higher (~35%) risk of gastric cancer was observed in association with high cholesterol consumption (pooled OR: 1.35, 95% CI: 1.29–1.62, I2 = 68%; 95%CI: 45–81%). Subgroup analysis also showed this positive relationship in population-based case–control studies, those conducted on non-US countries, those with a higher number of cases and high-quality studies, those that collected dietary data via interviews, studies not adjusted for Helicobacter pylori infection, and studies where the body mass index was controlled. Besides, a non-linear dose–response association was also identified (P = 0.03).Conclusion: This study demonstrated that dietary cholesterol intake could significantly augment the risk of gastric cancer in case–control studies. Prospective cohort studies with large sample sizes and long durations of follow-up are required to verify our results.


PLoS ONE ◽  
2014 ◽  
Vol 9 (12) ◽  
pp. e116060 ◽  
Author(s):  
Pengfei Kong ◽  
Qingqing Cai ◽  
Qirong Geng ◽  
Jing Wang ◽  
Yadong Lan ◽  
...  

2015 ◽  
Vol 40 (1) ◽  
pp. 148-157 ◽  
Author(s):  
Jennifer Straatman ◽  
Nicole van der Wielen ◽  
Miguel A. Cuesta ◽  
Elly S. M. de Lange – de Klerk ◽  
Elise P. Jansma ◽  
...  

2020 ◽  
Vol 29 (2) ◽  
pp. 191-198 ◽  
Author(s):  
Thin Thin Win ◽  
Saint Nway Aye ◽  
Joyce Lau Chui Fern ◽  
Cheng Ong Fei

Background and Aims: The latest meta-analysis on the role of aspirin on various cancers was published in early 2018. By including the latest and updated primary observational studies, we aimed to conduct this systematic review and meta-analysis to synthesize stronger evidence on the role of aspirin in reducing gastric cancer (GC) risk. Methods: The PubMed, Scopus, and MEDLINE databases were systematically searched up to December 2019 to identify relevant studies. Random-effects model was used to calculate summary ORs and 95%CI for I 2 >50%. If the heterogeneity is not significant, the fixed-effects model was used. Overall analysis of the studies, inverse variance weighting after transforming the estimates of each study into log OR and its standard error were used. Results: 21 studies were included in this meta-analysis. Results showed that aspirin significantly reduced the GC risk (OR=0.64, 95%CI=0.54-0.76) with substantial heterogeneity (I 2 =96%). Effect of GC risk reduction in low dose (OR=0.80, 95%CI=0.59-1.09) is slightly greater than high dose aspirin (OR=1.08, 95%CI=0.77-1.52). Protective effect of aspirin uses >5 years (OR=0.67, 95%CI=0.34-1.31) was greater than <5 years (OR=1.01, 95%CI=0.72-1.43) Conclusion: In conclusion, this meta-analysis showed that low dose aspirin with longer duration of more than 5 years were associated with a statistically significant reduction in GC risk. However, due to possible confounding variables and bias, these results should be cautiously treated.


Sign in / Sign up

Export Citation Format

Share Document